A Strategic Approach for Applying 3D Human In Vitro Models and Methodologies to Bridge the Gap between In Vitro and In Vivo – The drug-induced liver injury (DILI) case
Despite ongoing investments in research, advances in technology, and improved knowledge and understanding of human disease modeling, approximately 90% of new drugs entering clinical trials fail, largely due to safety issues in clinical phases or drug efficacy issues in patients. Why?
Because preclinical approaches that use in vivo animal models and in vitro cell models for discovery and development still do not reliably translate to patients.
In this webinar, InSphero CSO Prof. Armin Wolf discusses how the research community gets “lost in translation” and shares his strategy for bridging the divide between preclinical and clinical research to bring safe, effective drugs to market – and to patients in need of new therapeutics.
Prof. Armin Wolf will introduce a “causality assay” framework for evaluating drug-induced liver injury (DILI) with novel 3D in vitro models and methodologies, and explain how multicellular 3D human liver spheroids can be used for investigating a broad range of experimental conditions using a variety of analytical methods, from liver enzyme markers and histological techniques to the latest ‘omics technologies. He'll also walk you through several examples of successful applications of causality assays for the deconvolution of major DILI mechanisms – and offer his vision for the future of 3D in vitro tools for translational liver toxicology – and beyond.
You will learn:
- The challenges of drug discovery and translation (from in vitro and in vivo models to patients)
- The current gold standard: ATP-based DILI hazard identification
- Stepping beyond ATP: from hazard identification to risk assessment
- Impact of 3D spheroid models in drug development
- Future challenges and opportunities